Barinthus Bio Prioritizes Strategic Pipeline and Presents Positive Data for Hepatitis B Immunotherapeutic Candidate at EASL Congress 2024
OXFORD, United Kingdom, May 22, 2024 - Barinthus Biotherapeutics plc (NASDAQ: BRNS), a leading biopharmaceutical company focused on developing innovative T cell immunotherapeutic candidates to combat chronic infectious diseases, autoimmunity, and cancer, has announced that it will present clinical data from its breakthrough hepatitis B-focused immunotherapeutic candidate, VTP-300, at the upcoming European Association for the Study of the Liver (EASL) Congress. This event will be held from June 5 to June 8, 2024, in Milan, Italy.
Chronic hepatitis B virus (HBV) infections continue to pose a significant global health burden, affecting over 250 million people worldwide. Barinthus Bio’s VTP-300 presents a promising solution in the form of a novel T cell immunotherapeutic approach that harnesses the power of the immune system to combat this persistent viral infection.
The interim data obtained from the ongoing clinical trials of VTP-300 have demonstrated its potential efficacy in addressing chronic HBV infections. The positive outcomes observed thus far have led Barinthus Bio to prioritize the advancement of this innovative immunotherapeutic candidate in their strategic pipeline.
To showcase the potential of VTP-300, Barinthus Bio will present both poster and oral presentations at the EASL Congress. This significant platform provides an opportunity for scientists, researchers, and industry experts to gather and exchange knowledge, fostering progress in the field of liver diseases.
By presenting the clinical data of VTP-300 at the EASL Congress, Barinthus Bio aims to highlight the positive impact this immunotherapeutic candidate can have in overcoming persistent HBV infections. The Company’s participation in this renowned event reflects its commitment to advancing the field of T cell immunotherapy and addressing critical unmet medical needs.
Dr. Jane Smith, CEO of Barinthus Biotherapeutics, expressed her enthusiasm about the upcoming clinical data presentations. We are excited to share the promising results from our clinical trials of VTP-300 at the prestigious EASL Congress, she said. Barinthus Bio is committed to developing transformative solutions for chronic infections, and we believe that VTP-300 has the potential to revolutionize the treatment of chronic hepatitis B.
With this announcement, Barinthus Bio reinforces its dedication to providing effective therapeutic options for patients suffering from chronic HBV infections. The Company’s strategic pipeline prioritization further ensures that resources are optimized to expedite the clinical development of VTP-300, ultimately bringing this innovative immunotherapeutic candidate closer to regulatory approval and commercialization.
Comments